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Abstract The purpose of the present study was to examine the
analgesic activity of six novel hybrid molecules, which demon-
strated in the previous research anticonvulsant activity in
the maximal electroshock seizure (MES) and subcutane-
ous pentylenetetrazole seizure (scPTZ) tests in mice. The
antinociceptive properties were estimated in three models of pain
in mice—the hot plate test, the formalin test, and in the
oxaliplatin-induced neuropathy. Moreover, extended anticonvul-
sant studies were carried out and the antiseizure activity was
investigated in the 6-Hz test. Considering drug safety evaluation,
the influence of compounds on locomotor activity and contextual
memory were checked. Furthermore, chosen molecules were
tested in vitro for potential hepatotoxicity. To explain the proba-
ble mechanism of action, the radioligand binding assays were
performed. In both phases of formalin test, analgesic activity
demonstrated compounds 4, 8, and 9. These agents relieved also
mechanical allodynia in oxaliplatin-inducedmodel of neuropath-
ic pain. At active doses, they did not influence locomotor activity
of mice. Moreover, for compounds 8 and 9, no deleterious effect
on memory was observed, but compound 4might induce mem-
ory deficits. All tested compounds (4, 5, 8, 9, 15, and 16)
inhibited psychomotor seizures with the ED50 values = 24.66–
47.21 mg/kg. The binding studies showed that compound 4 only
at the high concentrations revealed the effective binding to the
neuronal sodium channels and moderately binding to the L-type
calcium (verapamil site) channels and NMDA receptors. The
present preclinical results proved that novel hybrid molecules
demonstrate very promising anticonvulsant and analgesic
activity.
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Introduction
Epilepsy is a chronic neurological disorder that is associated with
various types of recurrent convulsive and non-convulsive sei-
zures. Although 70–80% of the patients with new onset epilepsy
have complete seizure control with current antiepileptic drugs,
more effective, better-tolerated treatments remains major unmet
need (Sidhu and Sadhotra 2016). Currently available first- and
second-generation anticonvulsant drugs are known to cause mul-
tiple adverse effects, including dizziness, diplopia, ataxia, and
drowsiness; therefore, they had a significant impact on quality
of life of people with epilepsy (Cramer et al. 2010).
Most anticonvulsant drugs were developed to treat epilep-
sy, and their therapeutic activity in other disorders, including
pain (neuropathic pain, migraine prophylaxis), neuromuscu-
lar, and bipolar disorders was proved later (Mantegazza et al.
2010). Evidence suggests that epilepsy and pain syndromes
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have common pathophysiological mechanisms. One of them
is hyperexcitability generated by the pathological expression
and redistribution of sodium and calcium channels. Some of
anticonvulsant drugs that block these channels are effective in
the treatment of neuropathic pain owing to the same selective
block of high-frequency action potential firing that accounts
for their protective activity against seizures. Among these
drugs, carbamazepine was found to be useful in the treatment
of trigeminal neuralgia, whereas the gabapentinoids (like
gabapentin and pregabalin) were efficacious drugs in diabetic
neuropathic pain and post-herpetic neuralgia (Kukkar et al.
2013; Mendlik and Uritsky 2015).
Taking into consideration the aforementioned facts, contin-
ued preclinical searching for new anticonvulsant drugs with
collateral antinociceptive activity are expected since they lead
to further advancements in the treatment of epilepsy as well as
neuropathic pain.
In the recent study, we demonstrated significant anticonvul-
sant activity of six new hybrid compounds in two classic animal
models of epilepsy, MES and scPTZ tests (Kamiński et al.
2015a). These two models MES and scPTZ tests are well
known as Bgold standards^ in preclinical studies for early de-
tection of anticonvulsant activity (Löscher and Schmidt 2011).
Because of the increasing role of anticonvulsant drugs for treat-
ment of neuropathic pain, studies on the search for new anti-
convulsant agents should also consider the evaluation of their
usefulness in the treatment of this type of neurological disorder
(Rogawski and Löscher 2004). Therefore, the first aim of the
present study was to evaluate analgesic activity of the selected
compounds. The antinociceptive properties were estimated in
the hot plate test of acute pain, the formalin model of persistent
pain, as well as in the oxaliplatin-induced neuropathic pain
model in mice. Looking for the new compounds with broad
spectrum of activity in animal models of epilepsy, the second
aim of the present experiments was to extend our anticonvul-
sant studies: tested compounds were also examined in the 6 Hz
model of pharmacoresistant limbic seizures. Moreover, the in-
fluence on spontaneous locomotor activity as well as cognition
in passive avoidance test were checked. Considering drug safe-
ty evaluation, which is important in the preclinical identification
of new active substances, they were tested for potential hepa-
totoxicity on human hepatocellular carcinoma cell line using
in vitro cellular model. To determine the probable mechanism
of anticonvulsant action for the chosen compound, in vitro ion
channels and receptor binding assays were carried out.
Materials and methods
Animals
All experiments were carried out on adult male CD-1 mice
(22–26 g). The animals were housed in plastic cages at room
temperature of 20 ± 2 °C under 12–12 h light-dark cycle. A
standard pellet diet and tap water were continuously available.
All the experiments were performed between 8 a.m. and 3
p.m., after a minimum 30-min acclimatization to the experi-
mental room. The animals were randomly assigned to the
experimental groups and killed by cervical dislocation imme-
diately after the experiment.
Drugs and chemicals
The investigated compounds, 4 (N-benzyl-2-(2,5-
dioxopyrrolidin-1-yl)propanamide), 5 (N-(2-chlorobenzyl)-
2-(2,5-dioxopyrrolidin-1-yl)propanamide), 8 (2-(2,5-
dioxopyrrolidin-1-yl)-N-(2-fluorobenzyl)propanamide), 9
(2-(2,5-dioxopyrrolidin-1-yl)-N-(3-fluorobenzyl)propanamide),
15 (N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)butanamide), and 16
(N-(2-chlorobenzyl)-2-(2,5-dioxopyrrolidin-1-yl)butanamide)
were synthesized at the Department of Medicinal Chemistry,
Jagiellonian University, Medical College in Krakow
(Scheme 1). The synthesis and preliminary pharmacological stud-
ies of the investigated compounds was presented in our previous
study (Kamiński et al. 2015a). For the in vivo experiments, the
tested agents were suspended in a 0.5% solution of methylcellu-
lose (Loba Chemie, Germany). Lacosamide (Vimpat, UCB
Pharma, Belgium), levetiracetam (Sigma-Aldrich, Germany),
and valproic acid (Sigma-Aldrich, Poland) were dissolved in sa-
line solution. Formaldehyde (POCH, Poland) was dissolved in
distilled water. Oxaliplatin (Tocris Bioscience, UK) was prepared
in a 5% aqueous solution of glucose. All drug solutions/
suspensions were prepared freshly and given intraperitoneally
(i.p.) in a volume of 10 ml/kg. The tested compounds were ex-
amined at the dose which was its median effective dose (ED50)
determined in the MES test in the previous study (Table 1)
(Kamiński et al. 2015a). In the initial anticonvulsant evaluations
in the 6-Hz test, the animals were administered with a constant
dose of 100 mg/kg of each compound and experiments were
carried out 0.25, 0.5, 1, and 2 h after i.p. injection (Rapacz et al.
2016a). Then the ED50 values were established at previously
estimated time of peak effect. Reference drugs were administered
as follows: lacosamide and valproic acid, 30 min, and levetirace-
tam, 60 min, before the tests. The pretreatment times before the
testing of reference anticonvulsant drugs were based upon infor-
mation about their biological activity from the literature and our
previous experiments (Rapacz et al. 2016b; Rybka et al. 2016).
Hot plate test
Antinociceptive activity in the hot plate test (model of acute
pain) was investigated as described previously (Rapacz et al.
2016b) using the hot plate apparatus (Hot/cold plate, Bioseb,
France). In this experiment, the latency to pain reaction (hind
paw licking or jumping) of mice to a nociceptive stimulus
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(55–56 °C) was recorded. The cutoff time was established to
60 s to avoid paw tissue damage.
Formalin test
The formalin test was performed according to Laughlin et al.
(2002). The experimental procedure of this model of tonic
pain was described in detail in our earlier studies (Rapacz
et al. 2016a; Rapacz et al. 2016b). Briefly, 20 μl of a 2.5%
formalin solution was injected into the dorsal surface of the
right hind paw of each mouse. Then, the animals were placed
individually into glass beakers and were observed for the next
30 min. Time spent on licking or biting the injected hind paw
in selected intervals, 0–5 (the acute nociceptive phase) and
15–30 min (the inflammatory phase), was measured in each
experimental group.
Spontaneous locomotor activity
Locomotor activity was recorded with photoresistor
actometers (Ugo Basile, Italy) as described previously
(Rapacz et al. 2016b). The tested or reference compounds
were administered i.p. at the doses corresponding to their
ED50 values from the MES test, which were obtained in our
previous studies (Kamiński et al. 2015a; Rybka et al. 2014) to
determine whether the compounds at active anticonvulsant
dose influence normal locomotor activity of mice. Mice were
individually placed in activity cages (40 × 40 × 30 cm) for a
30-min habituation period, and then the number of light-beam
crossings was counted during the next 30 min of the
experiment.
Oxaliplatin-induced neuropathic pain
Anitallodynic activity was examined in the model of neuro-
pathic pain induced by oxaliplatin as described in detail earlier
(Rapacz et al. 2016a; Sałat et al. 2014). Mechanical withdraw-
al thresholds were examined for all mice prior to oxaliplatin
injection to obtain normal baseline values of withdrawal
threshold to mechanical stimuli (control). Seven days after
post-oxaliplatin injection (10 mg/kg, i.p.), the effect of test
compounds on mechanical allodynia was assessed using the
electronic von Frey device (Panlab, Spain). Mice were placed
individually in test compartments on an elevated metal mesh
grid and allowed to acclimate for 30 min. After a habituation
period, each mouse was tested three times in the midplantar
region of hind paw, allowing at least 30 s between each mea-
surement. Subsequently, the animals were pretreated with the
examined agents or vehicle. Thirty minutes later, the animals
were tested again and mean values of mechanical withdrawal
threshold were determined for each mouse.
Passive avoidance step-through test
The effect of the tested and reference compounds on learning
abilities of mice was conducted using the passive avoidance
apparatus (Panlab/Harvard Apparatus, Spain) according to the
method described elsewhere (Łuszczki et al. 2008; Pytka et al.
2016). The mice underwent two separate trials: an acquisition
trial (conditioning phase) and a retention trial (testing phase)
24 h later. Thirty minutes before the acquisition trial, each
mouse was pretreated with the tested or reference compound
at the dose corresponding to its ED50 value from theMES test.
As a control, vehicle-treated (0.5% methylcellulose, i.p.) and
scopolamine-treated mice (1 mg/kg, i.p.) were also used. Each
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Scheme 1 Schematic structure of the tested compounds
Table 1 Dose of tested
or references compounds
which was used in the
present study (ED50
values determined in the
MES test)
Compound Dose
(mg/kg)
4 67.65
5 74.49
8 54.90
9 77.43
15 73.26
16 113.02
Valproic acid 252.74
Lacosamide 9.24
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animal was placed for 30 s in an illuminated light compart-
ment, and after this exploration period, the guillotine gate
between the light and the dark compartments was open. As
far as the mice came into the dark compartment, the gate was
closed and an electrical foot shock (0.2 mA for 2 s) was given
through the grid floor. On the following day, each mouse was
placed again in the white compartment and the latency time
between gate opening and entry into the dark compartment
was recorded for each animal. Mice, which avoided the dark
compartment for 180 s (cut of latency), were considered to
remember the foot shock from the acquisition trial. Better
memory performance was indicated by longer latency to enter
in the black compartment in the test phase than in the condi-
tioning phase (Sałat et al. 2016).
6 Hz psychomotor seizures
The 6-Hz test was performed according to Brown et al.
(1953) and Barton et al. (2001) as described in detail
earlier (Rapacz et al. 2016a). Psychomotor seizures were
induced via corneal stimulation (6 Hz, 32 mA, 0.2 ms
rectangular pulse width, 3-s duration) using a constant
current device (ECT Unit 57800, Ugo Basile, Italy).
During the stimulation, mice were gently restrained and
released into the observation cage immediately after cur-
rent application. In the vehicle-treated mice, the proce-
dure caused Bstunned^ posture associated with rearing,
forelimb clonus, automatic movements, and twitching of
the vibrissae and Straub tail. The main seizure end point
was the duration of the immobility. Mice resuming nor-
mal behavior within 10 s from the stimulation were con-
sidered as protected (Kaminski et al. 2004; Leclercq and
Kaminski 2015; Rapacz et al. 2016a). To evaluate the
ED50, at least three groups of animals were injected with
various doses of tested compounds. Each group consisted
of six animals. The ED50 was defined as the dose of
a drug protecting 50% of animals against the 6 Hz
seizures.
In vitro binding studies
The radioligand binding studies were performed commercial-
ly by Cerep (Celle I’Evescault, France). Selected compound 4
was evaluated in preparations from rat cerebral cortex (ion
channel binding, NMDA receptor binding), human recombi-
nant (CHO cells) (GABAA1 binding), or SH-SY5Y cells (hu-
man recombinant) (neuronal α4β2 nicotinic binding).
[3H]Batrachotoxinin for sodium channel (Brown 1986),
[3H]nitrendipine for L-type calcium channel (dihydropyridine
site) (Gould et al. 1982), [3H]D888 for L-type calcium chan-
nel (verapamil site) (Reynolds et al. 1986), [125I]ω-conotoxin
GVIA for N-type calcium channel (Wagner et al. 1988),
[3H]CGP 39653 for NMDA receptor (Sills et al. 1991),
[3H]muscimol for GABAA1 (alpha 1,beta 2,gamma 2) recep-
tor (Wang 2001), and [3H]cytisine for neuronal α4β2 nicotin-
ic receptor (Gopalakrishnan et al. 1996) were used as specific
radioligands, respectively. Compound binding was expressed
as a percentage of inhibition of the binding of a radioactively
labelled ligand.
Analysis of hepatotoxicity activity using in vitro cellular
model
Cell culture
Human cancer cells (Hep G2) ATCC® 59195™ were used in
the study. The cells were cultured in standard conditions
(37 °C, 5% CO2), in MEM medium (Sigma-Aldrich), supple-
mented with 10% FBS (Sigma-Aldrich) and antibiotics
(Sigma-Aldrich).
MTT test
The MTT assay (Cayman) was used to determine the cy-
totoxic effects of analyzed compounds. Briefly, the cells
were seeded at a density of 1 × 105 in 96-well plates.
Following overnight culture, the cells were then treated
with increasing doses of compounds (4 and 8) as well
as doxorubicin (positive control) and incubated for 24 h.
Following cell exposure to compounds for 24 h, 10 μl
MTT reagent was added to each well and after 3 h of
incubation (37 °C, 5% CO2), dark crystals (reduced
formazan) appeared in the bottom of the wells. Next, the
Crystal Dissolving Solution (Cayman) was added to each
well. Then the optical density (OD) of each well was
determined at 570 nm on plate reader (BioTek). The num-
ber of metabolically active living cells is directly propor-
tional to the absorbance of the samples. The results are
presented at diagram as the percentage of control
condition ± SEM.
Data analysis
The obtained results were statistically estimated using one-
way analysis of variance (ANOVA), followed by Dunnett’s
test or repeated measures ANOVA, followed by Bonferroni’s
multiple comparison test. The results from passive avoidance
task were assessed using Kruskal-Wallis analysis of variance,
followed by Dunn’s multiple comparison test. Differences be-
tween groups were considered as significant if p < 0.05. The
log-probit method described by Litchfield and Wilcoxon
(1949) was used to establish ED50 values with the 95% con-
fidence limits.
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Results
Antinociceptive activity in the hot plate test
As it was shown in Fig. 1 compounds 8, 9, and 16 prolonged
the latency time to pain reaction from 17.4 ± 1.4 (vehicle-
treated group) to 25.0 ± 2.3 (by 44%, comp. 8), 24.0 ± 3.0
(by 38%, comp. 9), and 25.1 ± 2.3 s (by 45%, comp. 16),
respectively, but not in a statistically significant way.
Compounds 4 and 5 only slightly prolonged the latency to
pain response, whereas compound 15 failed to induce analge-
sic action in this model of acute pain. Anticonvulsant drugs—
valproic acid and lacosamide—prolonged the latency time to
pain response from 19.1 ± 2.4 (vehicle-treated group) to
23.5 ± 1.7 (by 23%) and 22.0 ± 1.9 s (by 15%), respectively,
but the results were not statistically significant.
Analgesic activity in the formalin test
As shown in Fig. 2a–f, in the first (neurogenic) phase of the
test, four compounds, 4, 8, 9, and 16, significantly reduced the
duration of the licking response by 51 (p < 0.01), 52
(p < 0.05), 31 (p < 0.05), and 51% (p < 0.05), respectively.
In the second (inflammatory) phase of the formalin test, a
statistically significant analgesic activity was recorded for four
molecules: 4, 5, 8, and 9. The evaluation of the time course of
the antinociceptive activity at selected intervals showed that
only compound 4 strongly diminished the pain responses in
all intervals: between 15 and 20 min of the observation by
78% (p < 0.01), between 20 and 25 min by 88% (p < 0.05),
and between 25 and 30 min by 75% (p < 0.05). Compounds 5
and 8 attenuated the nocifensive response, in a statistically
important way between 15 and 20 min of the measurement
by 64 (p < 0.05) and 65% (p < 0.05), respectively, and in the
last part of observation, between 25 and 30 min: 5 by 52%
(p < 0.01) and 8 by 83% (p < 0.05). Compound 9 diminished
the pain responses in a statistically significant way between 20
and 25 min of the assay by 71% (p < 0.0001) and between 25
and 30 min of the test by 80% (p < 0. 0001). In the inflam-
matory phase also, compound 16 showed analgesic action, but
the results were not statistically significant. Compound 15 did
not display antinociceptive properties in any phase of this
model of tonic pain. Anticonvulsant drugs—valproic acid
and lacosamide—displayed significant antinociceptive effect
in this model of tonic pain, as they decreased the duration of
the licking response in both phase: in the first phase by 38
(p < 0.001) and 39% (p < 0.01), respectively, and in the second
phase in all intervals: between 15 and 20 min of the observa-
tion by 87 (p < 0.0001) and 70% (p < 0.001), between 20 and
25 min by 76 (p < 0.001) and 83% (p < 0.05), and between 25
and 30 min by 68 (p < 0.001) and 83% (p < 0.001), respec-
tively (Fig. 2g, h).
Influence on locomotor activity
Four of the tested compounds (4, 5, 8, and 9), as well as
lacosamide, did not significantly influence on spontaneous
locomotor activity inmice. Compound 15 reduced the number
of crossings registered with photoresistor actometers by 29%
but not in a statistically significant way. Strong impact on the
behavior of mice in this test was recorded for agent 16, which
inhibited the locomotor activity in studied animals by 86%
(p < 0.001). Moreover, the first-generation anticonvulsant
drug—valproic acid—at the tested dose demonstrated seda-
tive properties, since it significantly decreased locomotor ac-
tivity in mice by 62%. On the other hand, the second-
generation anticonvulsant drug lacosamide had no significant
influence on locomotor activity. The obtained results are pre-
sented in Fig. 3.
Antiallodynic activity in the oxaliplatin-induced
neuropathy
In the view of mentioned results, three compounds (4, 8, and
9) with significant analgesic activity in the formalinmodel and
without sedative properties were also examined in the
oxaliplatin-induced neuropathic pain. Mechanical allodynia
in oxaliplatin-treated mice was measured 7 days after injec-
tion. The mean force that caused paw withdrawal was
2.69 ± 0.03 g in the control group (animals not treated with
oxaliplatin), whereas this value range from 1.74 ± 0.05 to
1.88 ± 0.04 g, respectively, in the group of oxaliplatin-
Fig. 1 Effects of compounds 4, 5, 8, 9, 15, 16, valproic acid, and
lacosamide on response latency in the hot plate test in mice. Data are
presented as mean ± SEM. Statistical analysis of the results was
conducted using one-way analysis of variance (ANOVA), followed by
Dunnett’s test: NS, N = 8
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treated animals. As it is shown in Fig. 4, in neuropathic ani-
mals, all tested compounds (4, 8, and 9) attenuated tactile
allodynia, since they significantly elevated the pain sensitivity
threshold by 78, 92, and 58%, respectively (p < 0.0001 in all
Fig. 2 a–h Time course of the antinociceptive activity of compounds 4,
5, 8, 9, 15, 16, valproic acid, and lacosamide in the formalin test. Each
value represents the mean ± SEM. Statistical analysis of the result was
conducted using two-way repeated measures ANOVA, followed by
Bonferroni’s multiple comparison test. Results compared to vehicle-
treated mice at the same time points: *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001, N = 8
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groups). Previous research from our laboratory demonstrated
that pregabalin given at the dose of 30 mg/kg elevated pain
sensitivity threshold by 122% (p < 0.001) in neuropathic mice
(Sałat et al. 2014).
Influence on memory in the passive avoidance
step-through task
The effect of three selected compounds 4, 8, and 9, as well as
valproic acid and lacosamide, at the doses corresponding to
their ED50 values from the MES test, on memory, was inves-
tigated in the step-through passive avoidance test. In this test,
scopolamine, a well-known muscarinic antagonist, which in-
terferes with memory in animals and humans, was used as a
positive control (Kwon et al. 2010). In the acquisition phase,
the step-through latency was similar in all experimental
groups. In the retention phase of this test, all tested and refer-
ence compounds prolonged step-through latency time in mice
(vehicle group: from 12.2 ± 3.4 to 174.2 ± 4.3 s; scopolamine:
from 25.3 ± 4.3 to 36.2 ± 7.9 s; 4: from 14.1 ± 3.4 to
97.9 ± 24.2 s; 8: from 26.7 ± 12.0 to 123.9 ± 23.1 s; 9: from
29.9 ± 7.6 to 148.8 ± 22.2 s; valproic acid: from 16.9 ± 2.7 to
100.3 ± 25.5 s; lacosamide: from 15.7 ± 6.2 to 145.0 ± 20.4 s)
(Fig. 5). In the scopolamine-treated group, the prolongation of
latency time was significantly shorter compared to that of
vehicle-treated mice (p < 0.001). In turn, compounds 8 and
9 and lacosamide significantly prolonged step-through latency
time compared to the scopolamine-treated mice (p < 0.05 for
all), whereas for compound 4 and valproic acid the results
were not statistically significant.
Anticonvulsant activity in the 6-Hz test
The initial anticonvulsant screening of the tested compounds
in the 6-Hz test was performed at a fixed dose of 100 mg/kg.
The obtained results revealed that all compounds demonstrat-
ed protection in half or more of the animals. Compounds 4 and
8 showed prolonged antiseizure activity (at least of 50% pro-
tection) at four time points, whereas compounds 5 and 9
displayed antiseizure activity at three time points (0.25, 0.5,
and 1 h). Shorter lasting anticonvulsant effect was observed
for compounds 15 and 16, as they showed protection at 0.25
and 0.5 h (Table 2). Based on the preliminary results for tested
compounds, their median effective doses (ED50) in the 6-Hz
test were determined at time point of their peak antiseizure
activity. The obtained ED50 values, ranging from 24.66 (com-
pound 4) to 47.21 mg/kg (compound 16), are presented in
Table 3. Summarizing, in the 6-Hz test, the examined com-
pounds revealed higher activity than valproic acid but lower
than lacosamide.
Binding studies
In order to better understand the plausible molecular targets by
which tested compounds might act, for a selected agent (4),
the binding assays for sodium channel (site 2), L-type calcium
(dihydropyridine and verapamil sites), as well as for N-type
calcium channels were carried out using [3H]batrachotoxin,
Fig. 4 Effect of selected compounds 4, 8, and 9 on tactile allodynia in
oxaliplatin-treated neuropathic mice assessed 7 days after oxaliplatin
injection measured using von Frey test. Data are presented as
mean ± SEM. Statistical analysis of the results was conducted using
repeated measures ANOVA, followed by Bonferroni’s multiple
comparison test. Allodynic effect of oxaliplatin-treated vs. vehicle-
treated mice: ###p < 0.001. Antiallodynic effect of the tested
compounds vs. oxaliplatin-treated mice: ****p < 0.0001, N = 9–10.
OXPT oxaliplatin
Fig. 3 Effects of the tested and reference compounds on locomotor
activity in mice. Data are presented as mean ± SEM of beam breaks
recorded for 30 min. Statistical analysis of the results was conducted
using one-way analysis of variance (ANOVA), followed by Dunnett’s
test. Significant difference was compared to the vehicle-treated group:
**p < 0.01, ***p < 0.001, N = 8
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[3H]nitrendipine, [3H]D888, and [125I]ω-conotoxin GVIA, as
radioligands, respectively. Moreover, the binding studies for
NMDA, GABAA and neuronalα4β2 nicotinic receptors were
performed. Compound 4 only at the high concentration of
500 μM revealed the effective binding to the neuronal sodium
channels (site 2), as it is indicated by the inhibition greater
than 50%. At this concentration, it also revealed moderately
influence on L-type calcium channels (verapamil site), 45%,
as well as did not bind to L-type calcium (dihydropyridine
site) and N-type calcium channels. At a concentration of
200 μM, the tested molecule revealed also moderate affinity
to NMDA receptors (antagonist radioligand). Compound 4 at
a concentration of 100 μM did not bind effectively to sodium
(site 2), L-type calcium (dihydropyridine and verapamil sites),
and N-type calcium channels as well as GABAA and neuronal
α4β2 nicotinic ionotropic receptors. The binding results are
shown in Table 4.
Potential hepatotoxicity activity
The MTT assay revealed that both tested compounds (4 and
9), at a concentration range of 10–50 μM, were safe (cell
viability: above 90%); only slight cytotoxic effects appeared
at higher concentrations of tested compounds (100 and
250 μM), but cell viability was still high (above 80%). In
addition, cytotoxicity effect of chemotherapeutic agent—
doxorubicin (anthracycline antibiotics)—on Hep G2 cells
was evaluated as positive control at the same concentration
as evaluated compounds (Fig. 6). Strong cytotoxic effect on
Hep G2 cells of doxorubicin was observed even at low con-
centrations (under 50 μM). Performed experiments show that
both compounds (4 and 9) did not induce hepatotoxic effects.
Discussion
Hybrid molecules are suggested to be a more effective and
safer remedy for treatment of various diseases than
Fig. 5 Effects of compounds 4, 8, 9, valproic acid, lacosamide, and
scopolamine on learning and memory in the passive avoidance test.
Data are presented as mean ± SEM in the acquisition phase (day 1) and
in the retention phase (day 2). Statistical analysis of the results was
conducted using Kruskal-Wallis test, followed by Dunn’s multiple
comparison test. Significant difference was compared with the vehicle-
treated mice: ###p < 0.001. Significant difference was compared with the
scopolamine-treated mice: *p < 0.05, ***p < 0.001, N = 8–10
Table 2 Anticonvulsant
activity of the tested
compounds in the 6-Hz
test following i.p.
administration in mice
(dose of 100 mg/kg)
Cmpd 6-Hz test
0.25 h 0.5 h 1 h 2 h
4 3/4 3/4 3/4 2/4
5 4/4 4/4 3/4 0/4
8 4/4 4/4 2/4 2/4
9 4/4 4/4 2/4 0/4
15 4/4 3/4 0/4 0/4
16 2/4 4/4 0/4 0/4
Data indicate number of mice protected/
number of mice tested. Ratios where at
least two animals were protected have
been highlighted in italics for easier data
interpretation. The animals were examined
at four pretreatment times: 0.25, 0.5, 1, and
2 h
Table 3 The quantitative pharmacological parameters ED50 values in
the 6-Hz test following i.p. administration in mice
Compound TPE
(h)
ED50
(mg/kg)
4 0.25 24.66 (18.13–33.55)
5 0.25 31.97 (19.66–51.98)
8 0.25 33.79 (12.79–89.29)
9 0.25 40.49 (24.26–67.58)
15 0.25 38.75 (23.48–63.94)
16 0.5 47.21 (34.29–65.02)
Valproic acid 0.5 130.64 (117.61–145.19)
Lacosamide 0.5 5.25 (3.55–7. 76)
TPE time to peak effect
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combination therapy (Kleczkowska et al. 2016). Our previous
research in the group of new hybrid molecules, which join on
the one chemical template the structural fragments of well-
known anticonvulsant drugs such as ethosuximide (effective
in the scPTZ seizures), levetiracetam (active in the 6-Hz test),
and lacosamide (active in the MES and the 6-Hz tests), proved
that a number of these agents revealed prominent anticonvul-
sant properties and broad spectrum of activity in animal
models of seizures, i.e., MES, scPTZ, and 6-Hz tests
(Kamiński et al. 2015a, b, 2016a). Furthermore, some deriva-
tives of pyrrolidine-2,5-dione demonstrated analgesic and
antiallodynic properties in the formalin model of tonic pain
and in oxaliplatin-induced neuropathy (Kamiński et al. 2016b;
Obniska et al. 2015a, 2016; Rapacz et al. 2016a, b). Therefore,
and as well as because of the increasing role of anticon-
vulsant drugs in the treatment of pain, the first aim of the
present study was evaluation of antinociceptive activity of
six selected hybrid amides derived from N-benzyl-2-
(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-
dioxopyrrolidin-1-yl)butanamide, based on the previously
obtained preliminary results (Kamiński et al. 2015a).
Among these compounds, four of them, 4, 8, 15, and
16, demonstrated anticonvulsant activity in the MES and
the scPTZ tests, whereas two of them, 5 and 9, were
active only in the MES test. All these compounds revealed
substantial safety profiles in the rotarod test for acute neu-
rological toxicity (TD50 >300 mg/kg (4, 5, 8, 15, and 16)
and TD50 >500 mg/kg (9), i.p., mice) that provided dis-
tinctly better protective indices compared to model anti-
convulsant drugs (carbamazepine, ethosuximide, and
valproic acid) and similar to that obtained for lacosamide
(Kamiński et al. 2015a).
Table 4 In vitro binding assays for compound 4
Assay Ligand Concentration [μM] % Inhibition of control
specific binding
Na+ channel site 2 (antagonist radioligand) [3H]batrachotoxinin 100 15.9
500 56.0
L-type Ca2+ (dihydropyridine site)
(antagonist radioligand)
[3H]nitrendipine 100 −14.8
500 0.7
L-type Ca2+ (verapamil site) (antagonist radioligand) [3H]D888 100 15.0
500 45.0
N-type Ca2+(antagonist radioligand) [125I]ω-conotoxin GVIA 100 0.2
500 0.9
NMDA (antagonist radioligand) [3H]CGP 39653 100 15.0
200 35.0
GABAA1 (alpha 1,beta 2,gamma 2) (agonist radioligand) [3H]muscimol 100 −18.3
N neuronal alpha4beta2 (agonist radioligand) [3H]cytisine 100 3.0
Results showing an inhibition higher than 50% are considered to represent significant effects of the test compounds; results showing an inhibition
between 25 and 50% are indicative of moderate effect; results showing an inhibition lower than 25% are not considered significant
Significance and moderate effects have been highlighted in italics for easier data interpretation
Fig. 6 Viability of HepG2 cells
incubated in the presence of
selected compounds in
concentration range 10–250 μM
for 24 h. The graph shows results
from MTT assay expressed as the
percentage of control
condition ± SEM. Three
independent experiments were
performed. Doxorubicin was used
as positive control: *p < 0.05
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It has been reported in preclinical studies that numerous
anticonvulsant active agents which are active in the MES test
exert an antinociceptive action in the animal models of pain
(Löscher and Schmidt 2011; Obniska et al. 2015a, b).
Therefore, in the present study, antinociceptive activity of
the tested compounds were examined at the dose which was
its median effective dose (ED50) determined in the MES test.
At the same dose, their influence on spontaneous locomotor
activity and contextual memory was also checked. At first,
analgesic activity was investigated in the model of acute
pain—the hot plate test. However, both the test and the refer-
ence compounds, examined at the anticonvulsant active doses,
demonstrated no significant analgesic properties in this model
of acute pain. In the previous study, we reported that
lacosamide tested at higher dose—30 mg/kg—revealed sig-
nificant antinociceptive effect (Rapacz et al. 2016a, b). In the
next step, all compounds were also examined in the formalin
test of tonic pain. In the first (neurogenic) phase of the test,
four compounds, 4, 8, 9, and 16, as well as valproic acid
and lacosamide statistically significantly attenuated the
nocifensive response. In the second phase of the formalin test,
a very prominent antinociceptive activity demonstrated com-
pounds 4, 5, 8, and 9,as well as reference anticonvulsant
agents. Also in other studies, anticonvulsant drugs, including
lacosamide and tiagabine, revealed analgesic activity in both
phases of the formalin test (Beyreuther et al. 2006; Laughlin
et al. 2002; Rapacz et al. 2016b; Stöhr et al. 2006). On the
other hand, lamotrigine and gabapentin inhibited only the late
phase formalin behaviors (Laughlin et al. 2002). Recently, it
has been reported that valproic acid at a dose of 300 mg/kg
showed a significant reduction in the acute and inflammatory
phases , but at a dose of 100mg/kg, it reduced significantly the
licking time only in the inflammatory phase (Kaufmann et al.
2016). The first phase of the formalin test is connected with
acute chemical pain, whereas the second one is defined as
tonic nociception involving central sensitization of dorsal horn
neurons of the spinal cord or inflammation-induced hyperac-
tivity of afferent nociceptors or combination of both (Laughlin
et al. 2002; Ximenes et al. 2013). Thus, it is suggested that
anticonvulsant drugs have more considerable effect on the
inhibition of sensitized signaling than on normal transient no-
ciceptive signaling (Laughlin et al. 2002).
Regretfully, all known anticonvulsant drugs often pro-
duce adverse effects, which range from mild disturbances
of CNS functions to serious cases of liver insufficiency or
bone marrow damage (Lasoń et al. 2011). To evaluate
whether compounds possess the ability to induce CNS de-
pression, and in this way influence antinociceptive effect,
the spontaneous locomotor activity was measured.
Compounds 4, 5, 8, 9, 15, and lacosamide at the tested
doses did not exhibit sedative properties, whereas com-
pound 16, as well as valproic acid, significantly diminished
locomotor activities.
Subsequently, selected compounds 4, 8, and 9, which re-
vealed prominent antinociceptive activity in the formalin test
as well as without sedative properties, were examined to es-
tablish their antiallodynic efficacy in the model of painful
peripheral neuropathy induced by a chemotherapeutic
drug—oxaliplatin (Ling et al. 2008). Many reports have indi-
cated that gabapentinoids significantly inhibited allodynia in-
duced by oxaliplatin or paclitaxel (Aoki et al. 2014; Gauchan
et al. 2009; Xiao et al. 2007). In the present study, compounds
4, 8, and 9 demonstrated a prominent elevation of mechanical
nociceptive threshold in oxaliplatin-treated mice. All tested
compounds significantly reduced mechanical hypersensitivity
and completely reversed oxaliplatin-induced allodynia in the
von Frey test. Previous research from our laboratory demon-
strated that pregabalin, which is used in the treatment of
neuropatic pain, strongly and significantly elevated pain sen-
sitivity in neuropathic mice (Sałat et al. 2014).
Most commonly used antiepileptic drugs (including phe-
nytoin and valproic acid) worsen learning and memory in the
patients with epilepsy (Cloyd et al. 2006). On the other hand,
the change in pharmacokinetics and higher sensitivity to ad-
verse effects of many antiepileptic drugs associated with aging
generally necessitate more cautious selection of drugs and
dosing in elderly people (Schmidt and Schachter 2014).
Thus, it is important in preclinical studies to control possible
CNS adverse effects, like diminished attention, language
skills, memory, and processing speed. Herein, to assess the
effects of the tested compounds on learning and memory, a
passive avoidance test was used. Compounds 8 and 9 and a
new-generation anticonvulsant drug—lacosamide—did not
cause cognitive deficits, as they significantly prolonged step-
through latency time compared to the scopolamine-treated
mice. In the case of compound 4 and first-generation anticon-
vulsant drug, valproic acid, this prolongation of the latency
time was lower and not statistically significant.
Data on hepatotoxicity of some antiepileptic drugs, includ-
ing valproic acid (Nanau and Neuman 2013), lamotrigine (Su-
Yin et al. 2008), and pregabalin (Sendra et al. 2011), became
the premise for determination of potential hepatotoxicity of
selected compounds possessing anticonvulsant activity.
Therefore, selected compounds 4 and 9 were evaluated for
potential cytotoxicity against human cancer cells (Hep G2).
Performed experiments showed that tested compounds did not
induce cytotoxic effect on hepatoma cells.
The second aim of the present study was to extend anticon-
vulsant studies of selected molecules using the 6-Hz test.
Psychomotor seizures induced by a 6 Hz stimulation is
deemed to be a model of therapy-resistant partial seizures
(Barton et al. 2001). The model reference drug, levetiracetam,
which is highly active in this model (ED50 = 15.73 mg/kg)
(Rapacz et al. 2016a), does not protect rodents against seizures
in the MES and scPTZ tests up to doses of 500 mg/kg—the
most widely used tests in the preclinical studies (Löscher and
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Schmidt 2011; Schmidt and Schachter 2014). Therefore, the
6-Hz test is proposed to be used routinely, apart from MES
and scPTZ tests to screen numerous novel molecules in pre-
clinical studies. In the present study, all of tested new hybrid
agents (4, 5, 8, 9, 15, and 16) displayed anticonvulsant prop-
erties in the psychomotor seizures test with ED50 values rang-
ing from 24.66 to 47.21 mg/kg.
Current clinically potent anticonvulsant drugs affect vari-
ous molecular targets, including modulation of voltage-gated
ion channels, enhancement of GABAergic transmission,
blockade of ionotropic glutamate (NMDA, AMPA) receptors,
or interactions with elements of the synaptic release machin-
ery (SV2a protein), and most have more than one mechanism
of action (Lynch et al. 2004; Klitgaard et al. 2016). It is worth
mentioning that regardless of the mechanism of action, they
all act to reduce hyperexcitability by either decreasing excit-
atory or enhancing inhibitory neurotransmission (Löscher
et al. 2016). Voltage-dependent sodium and calcium channels
seem to play a crucial role in establishing and regulating the
excitability of CNS nerves and are the most common targets
among currently available anticonvulsant drugs, including
phenytoin, carbamazepine, lamotrigine, oxcarbazepine, and
lacosamide (Brodie et al. 2011; Liu et al. 2003; Mantegazza
et al. 2010). Interestingly, lacosamide, in contrast to the afore-
mentioned drugs, enhances the slow inactivation of sodium
channels without affecting the fast inactivation (Rogawski
et al. 2015). The anticonvulsant drugs which influence the
activity of high voltage-activated calcium channels are phe-
nytoin, felbamate, topiramate, lamotrigine, and levetiracetam
(Lukyanetz et al. 2002; Meldrum and Rogawski 2007; Shank
et al. 2000), whereas gabapentin and pregabalin interact with
the α2δ-1 subunit of neuronal voltage-dependent calcium
channels (Rogawski and Löscher 2004). Valproic acid is as-
sociated with several mechanisms of action, including GABA
potentiation, glutamate (NMDA) inhibition, sodium channel,
and T-type calcium channel blockade (Klitgaard et al. 2016).
This drug is widely used as anticonvulsant in partial and gen-
eralized convulsive seizures and absence seizures as well as in
migraine prophylaxis. Moreover, recent evidence points also
to the involvement of neuronal nicotinic receptors in epilepsy
and pain sensation (Fonck et al. 2005; Lloyd and Williams
2000). A numerically abundant nicotinic receptor subtypes
in the CNS are α4β2, α3β4, and α7 (Lukas et al. 1999). It
has been reported that carbamazepine and oxcarbazepine were
found to block neuronal α4β2 nicotinic receptors, which may
explain their particular efficacy in nocturnal frontal lobe epi-
lepsy that can be caused by mutant neuronal nicotinic recep-
tors (Di Resta et al. 2010). Taking into account the previous
remarks, for selected compound 4, its influence on sodium
channel (site 2) and L-type and N-type calcium channels, as
well as for NMDA, GABAA, and neuronal α4β2 nicotinic
receptors, was performed. The results from the binding studies
showed that compound 4 only at the highest concentration of
500 μM revealed the effective binding to the neuronal sodium
channels (site 2) and moderate binding to the verapamil site of
L-type calcium channels. Moreover, at concentration of
200 μM, it binds moderately with NMDA receptors.
However, it should be stressed that the pharmacokinetic
studies for compound 4 have not been carried out and thus
the pharmacologically active in vivo concentration of this
molecule is not known. Therefore, the in vitro binding stud-
ies enable only the preliminary and tentative determination
of the mechanism of action. It is of interest to note that
carbamazepine, a well-known anticonvulsant drug that acts
as sodium blocker, showed also only a moderate effect on
sodium channels at concentration 500 μM (33.6% inhibition
of control specific binding) (Kamiński et al. 2016b). Bearing
in mind very promising anticonvulsant and analgesic prop-
erties of the tested hybrid molecules, as well as the fact that
currently available anticonvulsant drugs act by a variety of
mechanisms, further detailed studies in terms of plausible
molecular targets should be performed, especially including
the pharmacokinetic properties of the aforementioned
substances.
Conclusions
The results obtained in the present study indicate that
some of novel hybrid molecules derived from N-benzyl-
2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-
dioxopyrrolidin-1-yl)butanamide displayed prominent anal-
gesic effects in animal models of pain. In both phases of for-
malin test, antinociceptive activity demonstrated compounds
4, 8, and 9. These compounds relieved also mechanical
allodynia in oxaliplatin-induced neuropathic pain model. It
is noteworthy that at active doses, no sedative properties were
recorded for these compounds as well as lacosamide.
Moreover, for compounds 8 and 9 and lacosamide, no delete-
rious effect on memory was observed, while compound 4 and
valproic acid might induce memory deficits. Additionally, in
the MTT assay, tested compounds (4 and 9) did not induce
cytotoxic effect on hepatoma cells. The extended anticonvul-
sant studies proved that all tested compounds (4, 5, 8, 9, 15,
and 16) inhibited psychomotor seizures in the 6-Hz test.
Summing up, our previous and present preclinical results
proved that these novel hybrid molecules demonstrate very
promising anticonvulsant and analgesic activity. Compounds
4 and 9 displayed not only a broad spectrum of anticonvulsant
activity but also collateral prominent analgesic and
antiallodynic properties.
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